Navigation Links
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced initiation of a new clinical trial designed to evaluate the safety and efficacy of its tumor necrosis therapy (TNT) agent Cotara(R) in patients with glioblastoma multiforme (GBM), a deadly form of brain cancer.

In pilot studies Cotara has shown encouraging results, demonstrating a 58% increase in the expected median survival time in a group of 28 patients suffering from recurrent late stage glioblastoma multiforme. This was considered a promising development in this serious and deadly disease, which kills half of its victims within 14 months of diagnosis.

Peregrine believes that combined positive data from this new study in India and ongoing U.S. glioblastoma trials would provide a foundation for advancing Cotara into Phase III trials.

"Cotara has demonstrated promising increases in survival in previous clinical studies of late stage glioblastoma patients, and we are optimistic that the very large population of glioblastoma patients served by our Indian study centers will facilitate timely enrollment in this important new trial," said Steven W. King, president and CEO of Peregrine. "We anticipate that positive data from this study, together with dosimetry and dosing data being collected in ongoing U.S. Cotara trials, will help us determine the optimal design of Phase III product registration trials."

This multi-center open label Phase II safety and efficacy study is designed to enroll up to 40 glioblastoma patients who have experienced a first relapse. The study's primary objective is to confirm the maximum tolerated dose of Cotara in patients with GBM at first relapse.

Secondary objectives include estimates of overall patient survival, progression free survival and the proportion of patien
'"/>




Page: 1 2

Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
5. Top Pharmaceuticals Influence Doctors Prescriptions
6. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
7. Personalized Medicine and Innovative Pharmaceuticals
8. Pravastatin Launched by Watson Pharmaceuticals
9. Tata Industries picks up stake in Indigene Pharmaceuticals
10. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
11. OPPI Opposes Draft National Pharmaceuticals Policy
Post Your Comments:
(Date:12/19/2014)... December 20, 2014 Today, Balfleet.com ... special-occasion outfits, announces its formal dress promotion. All the ... up to 60% off. , Balfleet.com is well-known for ... bridesmaid dresses, prom dresses, cocktail dresses and more. Its ... 30-day money-back guarantee, and they can create an elegant ...
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... OK (PRWEB) December 19, 2014 Eufaula, ... home to Lake Eufaula, the state’s largest lake with ... lakeside town is home to a little more than ... 1:00 P.M. on Saturday, the 6th of December. , ... its way through downtown Eufaula on Main Street. ...
(Date:12/19/2014)... print component of Vision and Hearing is distributed within ... with a circulation of approximately 230,433 copies and an ... nationally through a vast social media strategy and across ... To explore the digital version of the campaign, ... exclusive interview with Mark DeMontis , sharing his experience ...
(Date:12/19/2014)... News) -- Potentially illness-causing E. coli bacteria were found ... according to a new study. Researchers checked cilantro, ... farmers markets in Los Angeles and Orange counties in ... 150 samples tested, 24 percent were positive for E. ... the researchers. Both types of bacteria can cause ...
Breaking Medicine News(10 mins):Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... to varying degrees, that cigarette smoking causes cancer, the ... have// sued them, reveals an analysis of recent lawsuits, ... ,The authors looked at the opening and closing statements ... personal injury claims brought against major tobacco manufacturers between ...
... a major out break of hepatitis A, a viral infection, ... cases have been// identified for treatment, so far. Most of ... happen to be students from the Elmbank Middle school. ... from the West end of Toronto have been given vaccinations ...
... stem cells are primarily responsible for the relapse of colon ... grow into any tissue. ,Earlier researches have shown ... always return . These include breast cancer, blood cancer and ... of Toronto told reporters that researchers were aware that stem ...
... the scheme proposed to evaluate overseas trained doctors, has not ... public by the Council of Australian Governments (COAG) and was ... be need of the hour especially after a furore at ... 17 patients., ,AMA president Dr Mukesh Haikerwal said, ...
... gave the ‘go-ahead’ to market a genetically-engineered (GE) rice ... a// mess just 3 months ago regarding its alleged ... to market this crop came as a shock, especially ... plans of commercialization of the crop. ,Joseph ...
... cats and dogs over fears of the spread of bird ... cats so as to prevent further spreading// of the H5N1 ... a chicken farm last week. Animal health experts suggested that ... was no scientific evidence that cats or dogs could pass ...
Cached Medicine News:Health News:Fear Factor in Toronto: health officials fight Hepatitis A outbreak 2
(Date:12/19/2014)... 18, 2014 Radiology information ... is used to store, manipulate, and distribute patient ... patient tracking and scheduling system, result reporting, and ... with HIS and other databases improves the hospital ... patient scheduling, patient list management, radiology department workflow ...
(Date:12/19/2014)... REDWOOD CITY, Calif., Dec. 18, 2014 ... on the development of medical diagnostics based on ... of gas flow, today announced financial results for ... 30, 2014. "Following the completion of ... well positioned to maximize the recently initiated CoSense® ...
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
Breaking Medicine Technology:The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... , NEW YORK, ... research report is available in its catalogue: , ... , http://www.reportlinker.com/p0164335/Cardiac-Pacemakers---A-World-Market-Analysis.html , Pacemaker devices constitute ... market. The worldwide cardiac pacemakers market is characterized by ...
... ... a new market research report is available in its ... Global Market Perspective , http://www.reportlinker.com/p0164320/Electrodes-for-Medical-Devices---A-Global-Market-Perspective.html , ... muscle and nerve cells that are created by chemical ...
Cached Medicine Technology:Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 2Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 3Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 4Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 5Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 6Reportlinker Adds Electrodes for Medical Devices - A Global Market Perspective 7
... The PowerPac HV high-voltage power supply, with temperature ... output of 5,000 V, 500 mA, and 400 ... gel temperature between 0 and 90 degrees C ... data transfer. Power cord and instructions are provided. ...
... power supply, 100-120 and 220-240 ... V, 4-400 mA, and 75 ... built-in switch when using either ... power cord. Power cord and ...
... Ultrapure MB Grade PRODUCT SPECIFICATIONS Form: Granular, free-flowing ... to 0.05 Gel Point (3%): less than or equal ... to 75C Gel Strength (3%): greater than or equal ... equal to 10% Sulfate: less than or equal to ...
Agarose L03 is recommended for separations of DNA fragments = 1,000 bp....
Medicine Products: